Fluidic Analytics

Website: https://www.fluidic.com/

Fluidic Analytics- Understand the machinery of life

With the right tool, protein researchers can change the world around us.

Our award-winning technologies open doors for scientists to understand proteins and their behavior better than ever before. By characterizing proteins and their interactions, scientists can make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. Our revolutionary technologies give researchers a fundamentally new way to analyze proteins without compromise, because we truly believe the right tools in the right hands will change the world.

Proteome Sciences

Website: https://www.proteomics.com/

Proteome Sciences is a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry.  We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications. 

By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, we can detect over 8,000 proteins per sample.  With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated in either disease progression or drug treatment. 

Using our unique TMTpro isobaric mass tags, we can run up to 15 samples per single experiment thereby allowing relative protein quantification between samples.  By using a reference channel, multiple experiments can be performed sequentially, thereby allowing 30 to 100+ samples to be characterized in one project.   Sensitivity is equivalent to conventional ELISA in many cases.

In the clinical area, we offer single or multiplexed protein measurements on customer selected proteins either with or without a PTM.  Proteins selected can be either known previously, or more often detected above via our Discovery Services.  We can measure up to 100 multiplex proteins per sample in a GCLP accredited Targeted Mass Spectrometric assay using clinically relevant samples such as plasma and CSF. Again, sensitivity is equivalent to conventional ELISA in many cases.

BioTheryX

Website: https://www.biotheryx.com/

BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven clinical and commercial success to deliver efficacious therapies to patients with unmet medical needs focusing on orally available small molecules for the treatment of cancers and inflammatory diseases.  Our lead molecule is currently in Phase I clinical trial for Acute Myeloid Leukemia and high-risk MDS and our lead protein degradation “molecular glue” molecule (Protein Homeostatic Modulator or PHM®) will be in the clinic in 2021 for hematological malignancies. 

Aurelia Biosciences

Website: https://www.aureliabio.com/

Aurelia Bioscience is a UK based pre-clinical contract research organisation specialising in bioassay development, pharmacological profiling and compound screening. Scientists at Aurelia Bioscience have significant experience of different target classes and use cutting edge technologies to deliver client projects in a timely, efficient and cost-effective manner. They work in early stages of the drug discovery pipeline including target identification and validation, hit identification, hit to lead as well as lead identification and optimisation.

Bio-Techne

Website: http://www.tocris.com/tpd

Bio-Techne offers a complete solution for Targeted Protein Degradation research and development. To support scientists working in this rapidly growing field, we provide a unique range of tools and reagents as well as custom services.

• Active Degraders and Degrader Building Blocks: The Tocris brand has pioneered commercialization of tool Degraders for investigating the phenotypic consequences of targeted protein knockdown. Tocris also supplies chemical building blocks to enable researchers to generate their own Degraders and offers custom synthesis of bespoke panels of Degrader Building Blocks.

• Ubiquitin Proteasome System (UPS) Proteins and Assays: As the global leader in UPS related products, Boston Biochem provides proteins, antibodies and assay kits, as well as custom expertise in protein purification, characterization, modification, and assay development.

• Assays for Protein Degradation: Simple WesternTM systems from ProteinSimple simplify and accelerate the detection of Degrader-mediated protein knockdown by automating the entire protein separation and detection process.

NanoTemper

Website: https://nanotempertech.com/

NanoTemper Technologies is deeply committed to the best customer experience. Central to this is a strong focus on enabling researchers to easily, efficiently, and accurately perform protein characterization. With a broad offering of systems, software and consumables for evaluating binding affinities and protein stability, scientists in pharmaceutical, biotech or academic labs will find an optimized workflow, quality results and responsive customer support. Work with a deeply experienced and globally operating team, and realize the NanoTemper experience.

Liverpool ChiroChem

Website: https://www.liverpoolchirochem.com/

Liverpool ChiroChem (LCC) is a chemical technology innovator that produces chiral small molecules for biotech/pharmaceutical R&D. As the Home of Chiral N-Heterocycles, our initial focus is the production and supply of sp3-rich chiral N- heterocycles, readily accessible, chirally pure and available on scale. The harnessed expert synthetic technologies provide efficient access to a variety of novel, compact, chiral building blocks, in order to facilitate access to new chemical space for hit identification and potential further hit expansion. Finally, our proprietary products are ideally suited for DNA-Encoded Library synthesis and Fragment Based Lead Discovery, which many medicinal chemists consider to be the two leading areas of modern-day drug discovery.

Selvita

Website: https://selvita.com/

Selvita is one of the largest  integrated service providers in Europe, aiming to deliver comprehensive solutions within area of drug discovery, regulatory studies, as well as research and development.

Drug Discovery

Selvita has provided efficient and effective drug discovery support for pharma and biotech companies’ programmes based on broad capabilities and deep experience in small molecule drug discovery, starting from target validation up to the selection of a clinical candidate. Selvita is built on experience in assay development and screening, medicinal and synthetic chemistry, computer-aided drug design, structural biology, in vitro pharmacology, ADME/DMPK and analytical testing. Selvita also offers pharmacological and efficacy testing with in vivo models of disease available for variety of indications.

Regulatory Studies

Selvita has been providing also world-class pharma services in the field of drug testing and bioanalytical analyses. We offer services at every stage of the drug discovery process, from development and validation of methods, stability studies, to routine quality control testing.

The quality of our services has been repeatedly confirmed during the GMP and GLP inspections.

Research & Development

Selvita’s unique experience in the area of drug discovery and regulatory landscape allows us to undertake ambitious project relying on high quality synthetic organic chemistry. Our knowledge and expertise ranges across several sectors including biotech, pharma, agro-chemistry and industrial chemistry. Our chemists undertake even the most challenging projects comprising synthesis of impurities and metabolites, regardless of the scale. Within multidisciplinary project teams involving chemists, computational chemists and biologists we are ready to find compounds with defined biological activity.